Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42


Protein deregulation associated with breast cancer metastasis.

Chan KK, Matchett KB, McEnhill PM, Dakir el H, McMullin MF, El-Tanani Y, Patterson L, Faheem A, Rudland PS, McCarron PA, El-Tanani M.

Cytokine Growth Factor Rev. 2015 Aug;26(4):415-23. doi: 10.1016/j.cytogfr.2015.05.002. Epub 2015 May 31. Review.


MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer.

Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P, Fuxe J.

Oncogene. 2013 Dec 12;32(50):5614-24. doi: 10.1038/onc.2013.322. Epub 2013 Aug 19.


Transforming growth factor-β 1 enhances the invasiveness of breast cancer cells by inducing a Smad2-dependent epithelial-to-mesenchymal transition.

Lv ZD, Kong B, Li JG, Qu HL, Wang XG, Cao WH, Liu XY, Wang Y, Yang ZC, Xu HM, Wang HB.

Oncol Rep. 2013 Jan;29(1):219-25. doi: 10.3892/or.2012.2111. Epub 2012 Oct 30.


Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1.

Hedley BD, Welch DR, Allan AL, Al-Katib W, Dales DW, Postenka CO, Casey G, Macdonald IC, Chambers AF.

Int J Cancer. 2008 Aug 1;123(3):526-34. doi: 10.1002/ijc.23542.


Mechanisms involved in breast cancer liver metastasis.

Ma R, Feng Y, Lin S, Chen J, Lin H, Liang X, Zheng H, Cai X.

J Transl Med. 2015 Feb 15;13:64. doi: 10.1186/s12967-015-0425-0. Review.


MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.

Srivastava RK, Kurzrock R, Shankar S.

Mol Cancer Ther. 2010 Dec;9(12):3254-66. doi: 10.1158/1535-7163.MCT-10-0582. Epub 2010 Nov 1.


Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling.

Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G.

Cancer Res. 2008 Mar 1;68(5):1388-97. doi: 10.1158/0008-5472.CAN-07-2706.


The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis.

Imamura T, Hikita A, Inoue Y.

Breast Cancer. 2012 Apr;19(2):118-24. doi: 10.1007/s12282-011-0321-2. Epub 2011 Dec 3. Review.


Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.

Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X, Cai L.

Cancer Epidemiol. 2013 Dec;37(6):985-92. doi: 10.1016/j.canep.2013.08.005. Epub 2013 Sep 5.


Transforming growth factor-β signaling in tumor initiation, progression and therapy in breast cancer: an update.

Zu X, Zhang Q, Cao R, Liu J, Zhong J, Wen G, Cao D.

Cell Tissue Res. 2012 Jan;347(1):73-84. doi: 10.1007/s00441-011-1225-3. Epub 2011 Aug 16. Review.


MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis.

Yang F, Zhou X, Miao X, Zhang T, Hang X, Tie R, Liu N, Tian F, Wang F, Yuan J.

Breast Cancer Res Treat. 2014 May;145(1):23-32. doi: 10.1007/s10549-014-2915-9. Epub 2014 Apr 1.


Epithelial-mesenchymal transition (EMT) is not sufficient for spontaneous murine breast cancer metastasis.

Lou Y, Preobrazhenska O, auf dem Keller U, Sutcliffe M, Barclay L, McDonald PC, Roskelley C, Overall CM, Dedhar S.

Dev Dyn. 2008 Oct;237(10):2755-68. doi: 10.1002/dvdy.21658.


Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.

Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, van der Pluijm G.

Cancer Res. 2007 Sep 15;67(18):8742-51.


Transforming growth factor-beta1 regulation of ATF-3 and identification of ATF-3 target genes in breast cancer cells.

Kwok S, Rittling SR, Partridge NC, Benson CS, Thiyagaraj M, Srinivasan N, Selvamurugan N.

J Cell Biochem. 2009 Oct 1;108(2):408-14. doi: 10.1002/jcb.22267.


Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis.

Sin S, Bonin F, Petit V, Meseure D, Lallemand F, Bièche I, Bellahcène A, Castronovo V, de Wever O, Gespach C, Lidereau R, Driouch K.

J Natl Cancer Inst. 2011 Sep 7;103(17):1323-37. doi: 10.1093/jnci/djr290. Epub 2011 Aug 10.


TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells.

Gomes LR, Terra LF, Wailemann RA, Labriola L, Sogayar MC.

BMC Cancer. 2012 Jan 19;12:26. doi: 10.1186/1471-2407-12-26.


Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis.

Petersen M, Pardali E, van der Horst G, Cheung H, van den Hoogen C, van der Pluijm G, Ten Dijke P.

Oncogene. 2010 Mar 4;29(9):1351-61. doi: 10.1038/onc.2009.426. Epub 2009 Dec 14.


VDR status arbitrates the prometastatic effects of tumor-associated macrophages.

Zhang Y, Guo Q, Zhang Z, Bai N, Liu Z, Xiong M, Wei Y, Xiang R, Tan X.

Mol Cancer Res. 2014 Aug;12(8):1181-91. doi: 10.1158/1541-7786.MCR-14-0036. Epub 2014 May 12.

Supplemental Content

Support Center